Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-12-24
2000-03-21
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514824, 514390, A61K 31415
Patent
active
060403268
ABSTRACT:
The production of 3-deoxyglucosone, which is an intermediate in the Maillard reaction and induces a crosslinking glycation of proteins participating in various diseases, is inhibited with an inhibitor containing at least one parabanic acid derivative as an effective ingredient. The at least one parabanic acid derivative is represented by the following formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein, R is hydrogen or lower alkyl; X is hydrogen, alkyl, cycloalkyl, lower alkylcycloalkyl, phenyl or phenylalkyl which is optionally substituted with lower alkyl, lower alkoxy, nitro and/or halogen; and n is an integer of from 1 to 4. Inhibiting the production of 3-DG, which is a highly active intermediate which participates in the formation of crosslinked protein in the Maillard reaction is useful for the treatment and the prevention of various diseases induced by deposition into tissues or sclerosis or denaturation of crosslinked protein, or diseases induced by aging and diabetic complications.
REFERENCES:
patent: Re32919 (1989-05-01), Sarnoff
patent: 4096130 (1978-06-01), Kraft et al.
patent: 4647574 (1987-03-01), Ienaga et al.
patent: 4656034 (1987-04-01), Sarnoff
patent: 4658830 (1987-04-01), Sarnoff
patent: 4661469 (1987-04-01), Sarnoff
patent: 4683240 (1987-07-01), Ienaga et al.
patent: 4772585 (1988-09-01), Sarnoff et al.
patent: 4832682 (1989-05-01), Sarnoff
patent: 4985453 (1991-01-01), Ishii et al.
patent: 5002930 (1991-03-01), Sarnoff et al.
patent: 5078680 (1992-01-01), Sarnoff
patent: 5084473 (1992-01-01), Mikami et al.
patent: 5681843 (1997-10-01), Kotani et al.
Patton, J. Org. Chem.., 32, No. 2, pp. 383-388 (1967).
Yonezawa, et al., Nippon Kagaki Zasshi, 89, No. 8, pp. 62-64 (1968).
"Pathologic Biochemistry and Clinics of Free Radicals, Inflammation and Antiinflammation", Nippon Rinsho, vol. 46, No. 10, pp. 93-97 (1988).
Ogawva, et al., "Syntheses of substituted 2,4-dioxo-thienopyrimidine-1-acetic acid and their evaluation as aldose reductase inhibitor", European Journal Of Medicinal Chamistrychimica Theraputica, vol. 28, No. 10, 1993, pp. 769-782.
Kanazu, et al., "Aldehyde reductase is a major protein associated with 3-deoxyglucosone reductase activity in rat, pig and human livers", Biochem J., 279, 903-906 (1991).
Flynn, "Aldehyde Reductases: Monomeric Nadph-Dependent Oxidoreductases With Multfunctional Potential", Biochem. Pharmacol., vol. 31 No. 17, 2705-2712 (1982).
Morrison and Boyd, Organic Chemistry, Allyn and Bacon, Inc., Boston (1965), pp. 806, 808, 847-848.
Malamas, "Quinazolineacetic Acid and Related Anaslogs as Aldose Reductase Inhibitors" J. Med. Chem. (1990), 34,(4), 1492-503, abstract.
CA60:532c, abstract.
Gangier, "Reactivity of Nucleophilic Uracil Derivatives" J. Heterocycl. Chem. (1994), 31, (6), 1707-14, abstract.
Fujisawa Hiroki
Hotta Nigishi
MacMillan Keith D.
Nippon Zoki Pharmaceuticals Co., Ltd.
LandOfFree
3-deoxyglucosone production inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-deoxyglucosone production inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-deoxyglucosone production inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-730635